Silver Book Fact

“Over the past thirty-five years, U.S. age-adjusted mortality from cardiovascular disease declined 50 percent. This marked reduction reflects advances in the prevention, diagnosis, and treatment of common cardiovascular conditions.”

Weisfeldt, Myron L, and Susan L Zeiman. Advances in the Prevention and Treatment of Cardiovascular Disease: One of the most important contributors to improved human survival is the treatment of cardiovascular disease. Health Aff. 2007; 26(1): 25-37. http://content.healthaffairs.org/cgi/content/full/26/1/25

Reference

Title
Advances in the Prevention and Treatment of Cardiovascular Disease: One of the most important contributors to improved human survival is the treatment of cardiovascular disease
Publication
Health Aff
Publication Date
2007
Authors
Weisfeldt, Myron L, and Susan L Zeiman
Volume & Issue
Volume 26, Issue 1
Pages
25-37
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • Cost-effectiveness of SAVR
    The cost-effectiveness ratio for surgical aortic valve replacement (SAVR), compared to no surgery, was estimated at $13,528 per quality-adjusted life year (QALY) (~$17,225 in 2017 dollars).  
  • Between 1998 and 2008, the rate of death attributable to cardiovascular disease declined 30.6%.  
  • The greater use of medications and revascularization would provide approximately a 17% reduction in 2 year mortality combined.  
  • Cost-effectiveness of TAVR in sSAS patients
    Patients with severe symptomatic aortic stenosis (sSAS) considered to be at high surgical risk who underwent transcatheter aortic valve replacement (TAVR) experienced lifetime incremental cost-effectiveness ratios of $55,090 per QALY…  
  • Life expectancy and quality of life gains from AVR
    A study of 4,617 patients who underwent aortic valve replacement (AVR) over a period of 20 years found significant gains in life expectancy and quality of life — 43,166 net life-years…